You can buy or sell Conatus and other stocks, options, ETFs, and crypto commission-free!
Conatus Pharmaceuticals Inc. Common Stock, also called Conatus, is a biotechnology company, which engages in the development and commercialization of medicines for the treatment of liver diseases. Read More It focuses in development of emricasan, an orally active pan-caspase inhibitor, for the treatment of patients with chronic liver disease, which reduce the activities of human caspases. The company was founded by Alfred P. Spada, Jennifer Giottonini Cayer, and Steven J. Mento on July 13, 2005 and is headquartered in San Diego, CA.
San Diego, California
52 Week High
52 Week Low
Yahoo FinanceMar 22
Conatus (CNAT) Declines on Failure of NASH Fibrosis Study
Shares of Conatus Pharmaceuticals Inc. CNAT plunged 50.8% in after-hours trading, after it announced disappointing top-line results from the phase IIb ENCORE-NF study. Notably, shares of Conatus have plummeted 55.2% in the past six months compared with the industry’s decline of 4.7%. Conatus is conducting three phase IIb ENCORE studies on emricasan for treating fibrosis or cirrhosis induced by nonalcoholic steatohepatitis (NASH). The programs are named ENCORE-NF (for NASH fibrosis), ENCORE-PH (for portal ...
Conatus (NASDAQ:CNAT) Shares Fall By More Than 50% After Midstage Study Shows NASH Candidate Lagged Placebo
Shares of microcap biotech Conatus Pharmaceuticals Inc (NASDAQ: CNAT) are heading crashing following the release of results from a midstage trial of its non-alcoholic steatohepatitis candidate.
Markets InsiderMar 21
Conatus Announces Top-line Results from ENCORE-NF Phase 2b Clinical Trial in NASH Fibrosis
SAN DIEGO, March 21, 2019 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced top-line results from the company’s Phase 2b ENCORE-NF clinical trial in patients with biopsy-confirmed nonalcoholic steatohepatitis (NASH) and liver fibrosis. The trial’s primary endpoint was a ≥1 CRN fibrosis stage improvement with no worsening of steatohepatitis compared with placebo at week 72. “Although emricasan did not have the desired effect in these earlier-stage NASH fibrosis patients, we beli...
Expected May 1, After Hours